NCT07218926View on ClinicalTrials.gov

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

450

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

April 26, 2028

Study Completion Date

October 28, 2030

Conditions

Gastrointestinal Neoplasms

Interventions

DRUG

IDRX-42

IDRX-42 will be administered.

DRUG

Sunitinib

Sunitinib will be administered.

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY